+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Genome Editing Market Size, Growth & Analysis, By Type, By Application, By End-User, And Segment Forecasts To 2028

  • ID: 5360599
  • Report
  • September 2020
  • Region: Global
  • 244 pages
  • Reports and Data

FEATURED COMPANIES

  • GenScript
  • Lonza
  • Merck KGaA
  • New England Biolabs
  • Sangamo Therapeutics Inc.
  • MORE
Increasing incidence of genetic diseases and disorders, coupled with rising need for advanced genome editing are key factors driving market revenue growth.

Market Size - USD 4.98 Billion in 2020, Market Growth - CAGR of 14.8%, Market Trends - Rising investments by major players in research projects for advancements in genetic engineering, therapeutics, and treatments.

The global genome editing market size is expected to reach USD 14.96 Billion in 2028, and register a CAGR of 14.8% during the forecast period. Increasing prevalence of genetic disorders and various other chronic diseases, rising awareness regarding gene therapy, and increasing spending on R&D projects to find applications of genome editing.

Genome editing or gene engineering is the technology that offers the ability to make specific changes in the DNA sequence of a living organism and customizing its genetic formation for disease treatment, alter traits of the diseases or form the desired DNA sequence.

However, stringent regulatory scenario and ethical concerns for gene editing research and applications and concerns among end users regarding use of gene alteration therapies are factors that could hamper growth of the global genome editing market to some extent.

Some Key Findings From the Report:
  • Among the type segments, the Transcription Activator-Like Effector Nucleases (TALEN) segment accounted for 37.7% in 2020.
  • The Asia Pacific market size was USD 1.37 Billion in 2020, due to increasing investments in research and development projects and application of gene synthesis for genetic engineering in organisms, cells, and tissues, and in the field of CRISPR by major players in countries in the region.
  • Key players profiled in the report include Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Lonza, New England Biolabs, and Sangamo Therapeutics, Inc. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
  • In January 2020, NEB (New England Biolabs), which is a US-based provider of solutions supporting genome editing, synthetic biology, and next-generation sequencing, collaborated with a Europe-based biotechnology company, ERS Genomics, with intention to provide access to the foundational CRISPR-Cas9 in order to develop and commercialize CRISPR gene editing tools and reagents.
For the purpose of this report, the global genome editing market is segmented on the basis of type, application, end use, and region:

Type Outlook (Revenue, USD Billion; 2018 - 2028)
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • Transcription Activator-Like Effector Nucleases (TALEN)
  • Zinc Finger Nucleases (ZFN)
  • Others
Application Outlook (Revenue, USD Billion; 2018 - 2028)
  • Animal Genetic Engineering
  • Therapeutic Application
  • Genetically Modified Organisms
  • Plant Genetic Engineering
  • Cell Line Engineering
End Use Outlook (Revenue, USD Billion; 2018 - 2028)
  • Pharma-Biotech Companies
  • Academic Institutes & Research Center
  • Agrigenomic Companies
  • Contract Research Organizations
Region Outlook (Revenue, USD Billion; 2018 - 2028)
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Benelux
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Rest of Latin America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa
Reasons to Buy the Report
  • A robust analysis and estimation of the Genome Editing Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
  • A holistic competitive landscape of the all the major players in the Genome Editing Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
  • Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
  • Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
  • Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • GenScript
  • Lonza
  • Merck KGaA
  • New England Biolabs
  • Sangamo Therapeutics Inc.
  • MORE
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary
2.1. Summary Snapshot, 2017 – 2027

Chapter 3. Indicative Metrics
3.1. Rising number of research publications related to genetic engineering
3.2. Funding for genomic research
3.3. Rising incidence of target diseases across the globe
3.4. Increasing focus on infrastructure development for genomics and life science research

Chapter 4. Genome Editing Market Segmentation & Impact Analysis
4.1. Genome Editing Segmentation Analysis
4.2. Genome Editing Market Value Chain Analysis, 2017-2027
4.3. Regulatory framework
4.4. Genome Editing Market Impact Analysis
4.4.1. Market driver analysis
4.4.1.1. Favorable funding scenario
4.4.1.2. Technological advancements in genetic engineering
4.4.1.3. Rising prevalence of genetic diseases
4.4.1.4. Increasing focus of food industry on genetically modified organisms
4.4.2. Market restraint analysis
4.4.2.1. Stringent regulatory scenario and ethical concerns for gene editing research and applications
4.4.2.2. Concerns among end users regarding use of gene alteration therapies
4.5. Key opportunities prioritized
4.6. Industry analysis - Porter's
4.7. Genome Editing Competitive scenario, 2017

Chapter 5. Genome Editing Type Insights & Trends
5.1. Type Dynamics & Market Share, 2019 & 2027
5.2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
5.2.1. Market estimates and forecast, 2017 – 2027 (USD Million)
5.2.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
5.3. Transcription Activator-Like Effector Nucleases (TALENS)
5.3.1. Market estimates and forecast, 2017 – 2027 (USD Million)
5.3.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
5.4. Zinc Finger Nucleases (ZFNS)
5.4.1. Market estimates and forecast, 2017 – 2027 (USD Million)
5.4.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
5.5. Others
5.5.1. Market estimates and forecast, 2017 – 2027 (USD Million)
5.5.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)

Chapter 6. Genome Editing Application Insights & Trends
6.1. Application Dynamics & Market Share, 2019 & 2027
6.2. Animal Genetic Engineering
6.2.1. Market estimates and forecast, 2017 – 2027 (USD Million)
6.2.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
6.2.3. Therapeutic Application
6.2.3.1. Market estimates and forecast, 2017 – 2027 (USD Million)
6.2.3.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
6.2.4. Genetically Modified Organisms
6.2.4.1. Market estimates and forecast, 2017 – 2027 (USD Million)
6.2.4.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
6.3. Plant Genetic Engineering
6.3.1. Market estimates and forecast, 2017 – 2027 (USD Million)
6.3.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
6.4. Cell Line Engineering
6.4.1. Market estimates and forecast, 2017 – 2027 (USD Million)
6.4.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)
6.5. Others
6.5.1. Market estimates and forecast, 2017 – 2027 (USD Million)
6.5.2. Market estimates and forecast, by region, 2017 – 2027 (USD Million)

Chapter 7. Genome Editing Market Application Insights & Trends
7.1. Application Dynamics & Market Share, 2019 & 2027
7.2. Pharma-Biotech Companies
7.2.1. Market estimates and forecast, 2017 – 2027, (USD Million)
7.2.2. Market estimates and forecast, by region, 2017 – 2027, (USD Million)
7.3. Academic Institutes & Research Center
7.3.1. Market estimates and forecast, 2017 – 2027, (USD Million)
7.3.2. Market estimates and forecast, by region, 2017 – 2027, (USD Million)
7.4. Agrigenomic Companies
7.4.1. Market estimates and forecast, 2017 – 2027, (USD Million)
7.4.2. Market estimates and forecast, by region, 2017 – 2027, (USD Million)
7.5. Contract Research Organizations
7.5.1. Market estimates and forecast, 2017 – 2027, (USD Million)
7.5.2. Market estimates and forecast, by region, 2017 – 2027, (USD Million)

Chapter 8. Genome Editing Regional Outlook
8.1. Genome Editing market share by region, 2019 & 2027
8.2. North America
8.2.1. North America Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.2.2. North America Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.2.3. North America Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.2.4. U.S.
8.2.4.1. US Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.2.4.2. US Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.2.4.3. US Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3. Europe
8.3.1. Europe Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.2. Europe Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.3. Europe Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.4. Europe Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.3.5. Germany
8.3.5.1. Germany Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.5.2. Germany Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.5.3. Germany Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.5.4. Germany Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.3.6. France
8.3.6.1. France Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.6.2. France Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.6.3. France Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.6.4. France Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.3.7. U.K.
8.3.7.1. U.K. Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.7.2. U.K. Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.7.3. U.K. Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.7.4. U.K. Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.3.8. Spain
8.3.8.1. Spain Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.8.2. Spain Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.8.3. Spain Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.8.4. Spain Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.3.9. Italy
8.3.9.1. Italy Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.9.2. Italy Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.9.3. Italy Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.9.4. Italy Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.3.10. Rest of the Europe (RoE)
8.3.10.1. RoE Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.3.10.2. RoE Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.3.10.3. RoE Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.3.10.4. RoE Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.4.2. Asia Pacific Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.4.3. Asia Pacific Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.4.4. Asia Pacific Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.4.5. China
8.4.5.1. China Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.4.5.2. China Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.4.5.3. China Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.4.5.4. China Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.4.6. Japan
8.4.6.1. Japan Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.4.6.2. Japan Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.4.6.3. Japan Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.4.6.4. Japan Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.4.7. India
8.4.7.1. India Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.4.7.2. India Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.4.7.3. India Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.4.7.4. India Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.4.8. Rest of Asia-Pacific (RoAPAC)
8.4.8.1. RoAPAC Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.4.8.2. RoAPAC Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.4.8.3. RoAPAC Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.4.8.4. RoAPAC Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.5. Latin America
8.5.1. Latin America Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.5.2. Latin America Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.5.3. Latin America Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.5.4. Latin America Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.5.5. Brazil
8.5.5.1. Brazil Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.5.5.2. Brazil Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.5.5.3. Brazil Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.5.5.4. Brazil Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)
8.6. MEA
8.6.1. MEA Genome Editing market estimates and forecast, 2017 – 2027, (USD Million)
8.6.2. MEA Genome Editing market estimates and forecast by Type, 2017 –2027, (USD Million)
8.6.3. MEA Genome Editing market estimates and forecast by Application, 2017 –2027, (USD Million)
8.6.4. MEA Genome Editing market estimates and forecast by End User, 2017 –2027, (USD Million)

Chapter 9. Competitive Landscape
9.1. Market Revenue Share by Manufacturers
9.2. Market positioning
9.3. Strategy Benchmarking
9.3.1. Key Organic Strategies
9.3.2. Key Inorganic Strategies

Chapter 10. Company Profiles
10.1. Editas Medicine
10.1.1. Company Overview
10.1.2. Financial Insights
10.1.3. Products Offered
10.1.4. Strategic Initiatives
10.2. GenScript
10.2.1. Company Overview
10.2.2. Financial Insights
10.2.3. Products Offered
10.2.4. Strategic Initiatives
10.3. Horizon Discovery Group Plc
10.3.1. Company Overview
10.3.2. Financial Insights
10.3.3. Products Offered
10.3.4. Strategic Initiatives
10.4. Integrated DNA Technologies, Inc.
10.4.1. Company Overview
10.4.2. Financial Insights
10.4.3. Products Offered
10.4.4. Strategic Initiatives
10.5. Lonza
10.5.1. Company Overview
10.5.2. Financial Insights
10.5.3. Products Offered
10.5.4. Strategic Initiatives
10.6. Merck KGaA
10.6.1. Company Overview
10.6.2. Financial Insights
10.6.3. Products Offered
10.6.4. Strategic Initiatives
10.7. New England Biolabs
10.7.1. Company Overview
10.7.2. Financial Insights
10.7.3. Products Offered
10.7.4. Strategic Initiatives
10.8. Sangamo Therapeutics, Inc.
10.8.1. Company Overview
10.8.2. Financial Insights
10.8.3. Products Offered
10.8.4. Strategic Initiatives
10.9. Thermo Fisher Scientific Inc
10.9.1. Company Overview
10.9.2. Financial Insights
10.9.3. Products Offered
10.9.4. Strategic Initiatives
10.10. Transposagen Biopharmaceuticals, Inc
10.10.1. Company Overview
10.10.2. Financial Insights
10.10.3. Products Offered
10.10.4. Strategic Initiatives
Note: Product cover images may vary from those shown
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • GenScript
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies Inc
  • Lonza
  • New England Biolabs
  • Sangamo Therapeutics Inc.
Note: Product cover images may vary from those shown
Adroll
adroll